Canopy Growth (CGC) Competitors $3.05 +0.01 (+0.33%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CGC vs. ARVN, DAWN, ARDX, SYRE, CALT, SPRY, SNDX, ANIP, RCKT, and BCYCShould you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Canopy Growth vs. Arvinas Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Syndax Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Arvinas (NASDAQ:ARVN) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking. Do analysts prefer ARVN or CGC? Arvinas currently has a consensus price target of $63.50, suggesting a potential upside of 232.46%. Canopy Growth has a consensus price target of $3.50, suggesting a potential upside of 14.75%. Given Arvinas' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arvinas is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93Canopy Growth 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Does the MarketBeat Community favor ARVN or CGC? Arvinas received 165 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 67.03% of users gave Arvinas an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformArvinasOutperform Votes18567.03% Underperform Votes9132.97% Canopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% Which has more risk & volatility, ARVN or CGC? Arvinas has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Does the media refer more to ARVN or CGC? In the previous week, Arvinas had 7 more articles in the media than Canopy Growth. MarketBeat recorded 13 mentions for Arvinas and 6 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 1.00 beat Arvinas' score of 0.24 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARVN or CGC more profitable? Arvinas has a net margin of 0.00% compared to Canopy Growth's net margin of -186.17%. Arvinas' return on equity of -50.26% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets ArvinasN/A -50.26% -24.87% Canopy Growth -186.17%-74.29%-29.94% Which has better valuation & earnings, ARVN or CGC? Arvinas has higher earnings, but lower revenue than Canopy Growth. Arvinas is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$161.10M8.15-$367.30M-$4.67-4.09Canopy Growth$280.50M1.18-$487.23M-$4.93-0.62 Do insiders & institutionals believe in ARVN or CGC? 95.2% of Arvinas shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 5.2% of Arvinas shares are owned by company insiders. Comparatively, 1.3% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryArvinas beats Canopy Growth on 15 of the 18 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Canopy Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGC vs. The Competition Export to ExcelMetricCanopy GrowthMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$332.28M$396.46M$5.14B$9.31BDividend YieldN/AN/A4.81%4.06%P/E Ratio-0.6236.88135.1817.53Price / Sales1.186.071,235.42140.39Price / CashN/A10.6640.6537.95Price / Book0.821.994.884.92Net Income-$487.23M-$51.46M$118.97M$225.78M7 Day Performance-7.01%-0.97%16.19%-1.58%1 Month Performance-19.53%-4.25%16.02%6.67%1 Year Performance-37.55%-3.71%34.95%22.48% Canopy Growth Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGCCanopy Growth2.5326 of 5 stars$3.05+0.3%$3.50+14.8%-41.2%$332.28M$280.50M-0.621,029Short Interest ↓ARVNArvinas2.2909 of 5 stars$19.40-0.5%$63.50+227.3%-47.9%$1.33B$78.50M-4.18445Short Interest ↑DAWNDay One Biopharmaceuticals1.9456 of 5 stars$12.75flat$35.71+180.1%-11.4%$1.29B$101.95M-12.3860ARDXArdelyx3.8431 of 5 stars$5.38+3.1%$10.42+93.6%-21.2%$1.27B$251.85M-17.80267SYRESpyre Therapeutics1.9281 of 5 stars$24.56+1.8%$51.50+109.7%+63.0%$1.26B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)N/A$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.0568 of 5 stars$12.12+1.8%$24.00+98.0%+125.7%$1.18B$30,000.00-23.3390SNDXSyndax Pharmaceuticals3.9655 of 5 stars$13.76-1.2%$37.64+173.5%-34.4%$1.17B$16M-3.84110ANIPANI Pharmaceuticals4.8134 of 5 stars$55.69-1.6%$77.71+39.5%+5.5%$1.17B$555.46M-102.89642Short Interest ↓RCKTRocket Pharmaceuticals4.8614 of 5 stars$12.00-0.2%$51.00+325.0%-57.9%$1.09BN/A-4.37240Analyst RevisionBCYCBicycle Therapeutics3.5662 of 5 stars$15.31+10.9%$36.00+135.1%-13.5%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeHigh Trading Volume Related Companies and Tools Related Companies ARVN Competitors DAWN Competitors ARDX Competitors SYRE Competitors CALT Competitors SPRY Competitors SNDX Competitors ANIP Competitors RCKT Competitors BCYC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Canopy Growth Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Canopy Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGC Stock Alerts